Effect of RYR1 mutations on muscle spindle function and their impact on the musculoskeletal system
Profs. Susan Treves and Francesco Zorzato, University Hospital Basel
Abstract (lay summary see below)
Mutations in RYR1, the gene encoding the ryanodine receptor 1, the calcium channel of the sarcoplasmic reticulum, are the underlying cause of approximately 30% of all congenital myopathies. Patients usually present a range of phenotypes at a young age; these include developmental delays, muscle weakness, hypotonia and muscle stiffness that are primarily caused by defects in channel conductance or decreased amounts of ryanodine receptor protein, leading to less calcium being released from the sarcoplasmic reticulum. However, in addition to the skeletal muscle phenotype, many patients also present musculoskeletal defects including scoliosis, congenital hip dislocation, foot deformities, joint laxity etc. whose underlying causes have not been investigated.
Muscle spindles are an organ that is not involved in force generation, but act as mechanical sensors conveying information relating to muscle stretch and velocity of contraction to the central nervous system. This information is important not only for adjusting the tonic response of agonistic and antagonistic muscle groups, but also in modulating skeletal development. Indeed, patients with mutations in genes expressed in muscle spindles such as PIEZO2, exhibit musculoskeletal defects that are also present in patients harboring RYR1 mutations. We hypothesize that the skeletal deformities in patients harbouring RYR1 mutations are caused by malfunction of the intrafusal muscle fibres which make up the muscle spindles. Intrafusal muscle fibers which include nuclear bag fibers and nuclear chain fibers contain subplasmalemmal triads, a syncytium of sarcoplasmic reticulum and transverse tubules, i.e. the site of calcium release. In affected patients, mutations in RYR1 would cause abnormal calcium release from the ryanodine receptors 1 present in the intrafusal muscle fibers, bringing about an inappropriate response of the central nervous system ultimately leading to skeletal deformities during fetal development and/or growth.
We hypothesize that defective muscle spindle function is an etiological factor of the musculoskeletal defects in patients with RYR1-related congenital myopathy. We will investigate this by studying the role of ryanodine receptor 1 in intrafusal muscle fibers in: (i) a mouse model we created knocked in for compound heterozygous RyR1 mutations and (ii) in a muscle-spindle specific Ryr1 knock out mice.
Lay summary
Mutazioni nel RYR1, il gene codificante il recettore della rianodina (RyR1), sono la causa piu’
comune di malattie muscolari congenite nell’uomo, come la entral Core Disease, la Multi-minicore
Disease e la malattia Centronucleare. Molti pazienti affetti da queste patologie oltre a mostrare una
profonda debolezza muscolare, mostrano anche deformazioni del sistema scheletrico incluso scoliosi,
piede equino, pes cavus, cifosi, lassità articolare e contratture tendinee. Sino ad oggi nessuno studio si
è focalizzato sul nesso tra mutazioni nel RYR1 e deformazioni scheletriche.
L’obiettivo di questo progetto e’ di verificare se il malfunzionamento dei fusi muscolari,
causato da mutazioni nel RYRI sono la causa delle deformazioni scheletriche osservate nei pazienti con
mutazioni nel RYR1. I fusi muscolari sono un gruppo speciale di muscoli che giocano un ruolo
fondamentale nel trasmettere informazioni circa la velocità e l’estensione della contrazione muscolare,
al sistema nervoso centrale. Questo studio é importante perché permetterà di capire le basi molecolari
dei difetti scheletrici in questi pazienti, un passo fondamentale nel promuovere terapie per trattare i
pazienti affetti da malattie muscolari congenite dovute a mutazione nel RYR1.
Projekte
- Neue Forschungsprojekte ab 2024
- Die Bedeutung der Forschung
- Finanzierte Projekte
- Unstructured proteins as therapeutic targets for neuromuscular diseases
- Open and reproducible pipeline for the acquisition and analysis of muscle MRI data in Facioscapulohumeral Muscular Dystrophy
- Dissecting lysosomal signals to fight Pompe disease
- Functional properties and epigenetic signature of quiescent and early activated human muscle reserve cells
- Activation of human skeletal muscle stem cells:role of Orai3 ans its partner AHNAK2 in physiological condition and in Duchenne Muscular Dystrophy
- Understanding the clinical spectrum associated with VMA21 deficiency
- ANTXR2 as a key player in Collagen VI signaling in muscle stem cells: new therapeutic perspectives for COL6-related myopathies.
- Molecular mechanisms of complement activation and neuromuscular disruption by combinations of autoantibodies from patients with Myasthenia Gravis
- From the investigation of the role of SRSF1 in ALS/FTD to its targeting as a therapeutic strategy
- Molecular crosstalk between muscles and motor neurons and its role in neuromuscular circuit formation
- Molecular Diagnosis and Coping Mechanisms in Mitochondrial Myopathies
- IPRIMYO: Immune-privileged, immortal, myogenic stem cells for gene therapy of Muscular Dystrophy
- Effect of RYR1 mutations on muscle spindle function and their impact on the musculoskeletal system
- Therapeutic potential of human myogenic reserve cells in Duchenne Muscular Dystrophy
- Glutamine metabolism as a potential target for Duchenne Muscular Dystrophy
- Targeting protein s-acylation during Tubular Aggregate Myopathy
- Aggravating the phenotype of dystrophic mice for improving preclinical research and clinical translation for Duchenne muscular dystrophy
- Characterization of autoreactive T cells in Guillain-Barré syndrome
- A vascularized human muscle-on-a-chip to elucidate the contribution of endothelial-mesenchymal transition on the progression of muscular dystrophies
- Characterization of a novel form of ALS associated with changes in the sphingolipid metabolism
- Pre-clinical treatment of mouse models carrying recessive Ryr1 mutations with HDAC/DNA methyltransferase inhibitors.
- New aspects of TGFβ signaling in muscle homeostasis and regeneration
- Inhibition of sphingolipid synthesis as a treatment strategy for Duchenne muscular dystrophy
- Tamoxifen in Duchenne muscular dystrophy (TAMDMD)
- DNA aptamers against the DUX4 protein reveal novel therapeutic implications for FSHD
- Facilitating diagnosis of critical illness myopathy using muscle excitability testing
- Rapid Exploratory Imaging for High-resolution and Whole Extremity Coverage in MR Neurography
- Deciphering novel mechanisms and effectors contributing to muscle dysfunction in Myotonic Dystrophy Type I
- Can HDAC/DNA methyltransferase inhibitors improve muscle function in a congenital myopathy caused by recessive RYR1 mutations?
- Identification of the critical regulators of protein synthesis and degradation in human muscle atrophy
- Exploring peripheral B-cell-helper T cell phenotypes in the blood of patients with Myasthenia gravis using mass cytometry (CyTOF)
- Molecular signature, metabolic profile and therapeutic potential of human myogenic reserve cells
- A multicenter cross-sectional and longitudinal study of the Swiss cohort of Merosin-negative congenital muscular dystrophy
- Targeting NADPH oxidase 4 in models of Duchenne muscular dystrophy
- Characterizing the role of ER stress in C9orf72-linked ALS pathology
- Inducing mitophagy with Urolithin A to restore mitochondrial and muscle function in muscular dystrophy
- Motor unit action potentials analysis in patients with myopathies with a new wireless portable and multichannel Surface EMG device (WPM-SEMG)
- Role and therapeutic potential of PLIN3 in neuromuscular diseases
- Changes in ventilation distribution in children with neuromuscular disease using the insufflator/exsufflator technique: An observational study
- Mechanism and function of genome organization in muscle development and integrity
- Role and therapeutic potential of NADPH oxidases in a mouse model of Duchenne Muscular Dystrophy
- Characterization of pathological pathways activated in muscles of patients with congenital myopathies with disturbed Ca2+ homeostasis
- Creation of a study team to conduct an SMA 1-clinical trial at the Centre for Neuromuscular Diseases of the University Children's Hospital Basel (UKBB)
- Novel treatment to stop progressive neuropathy and muscle weakness in multifocal motor neuropathy
- Understanding the pathomechanisms leading to muscle alterations in Myotonic Dystrophy type I
- Automated volumetry and quantitative MRI to diagnose peripheral nerve lesions – translational proposal for a new clinical diagnostic imaging tool
- Novel approaches against Spinal Muscular Atrophy by targeting splicing regulators
- Protective effects and mechanisms of action of tamoxifen in mice with severe muscular diseases
- Role of the receptor FgfrL1 in the development of slow muscle fibers
- Muscle velocity recovery cycles: A new tool for early diagnosis of critical illness myopathy
- Generation of uncommitted human IPSC derived muscle stem cells for therapeutic applications
- Transposable vectors for dystrophin-expression in a murine model for muscular dystrophy
- Cardiac involvement in patients with Duchenne/Becker Muscular Dystrophy; an observational study
- Deciphering the pathogenic mechanisms of C9ORF72 ALS
- Enhancing estrogenic signalling to fight muscular dystrophies: Mechanisms of action and repurposing clinically approved drugs
- Mechanisms and therapeutic potential of modulating PGC‐1α to alter neuromuscular junction morphology and function
- Triggering human myoblast differentiation: from EGFR to myogenic transcription factors
- Improving cellular therapies of muscle dystrophies by uncovering epigenetic and signaling pathways of muscle formation
- Protein engineering in an attempt to increase the mechanical, integrin dependent cytoskeleton-matrix linkage in muscle fibers
- Muscle velocity recovery cycles: a new tool for characterization of muscle disease in vivo
- Excessive neurotrypsin activation and agrin cleavage-a pathogenic condition leading to sarcopenia-like muscle atrophy?
- Evaluation of novel treatment strategies for dyspherlinopathies in mouse models
- Cell therapy of LGMD2D by donor HLA-characterized human mesoangioblasts (hMABs) produced in GMP conditions
- In search of small molecules targeting protein-RNA complex: a novel approach against Spinal Muscular Atrophy
- Restoration of autophagy as a new strategy for the treatment of congenital muscular dystrophies
- Development of magnetic resonance methods for functional imaging of the skeletal muscle
- Targeting ER stress response: a potential mechanism for neuroprotection in Amyotrophic Lateral Sclerosis
- Generation of uncommitted human IPSC derived muscle stem cells for therapeutic applications
- Projektbroschüre
- SEAL Therapeutics AG
- Meetings und Seminare
- Teilnahme an Dachverbände
- Patientenregister
- Netzwerk Myosuisse
FSRMM
- Chemin des Saules 4B
2013 Colombier - +41 78 629 63 92
- philippe.rognon@fsrmm.ch